利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.011 秒)

    A DNA MOLECULE ENCODING A VARIANT PARAOXONASE AND USES THEREOF
    1.
    发明公开
    A DNA MOLECULE ENCODING A VARIANT PARAOXONASE AND USES THEREOF 审中-公开
    FOR对氧磷VARIANT DNA分子编码及其应用

    公开(公告)号：EP1370647A2

    公开(公告)日：2003-12-17

    申请号：EP02708387.2

    申请日：2002-03-20

    申请人： OY Jurilab Ltd.

    发明人： SALONEN, Jukka, T. ,  MARCHESANI, Marja ,  TUOMAINEN, Tomi-Pekka ,  KAIKKONEN, Jari

    IPC分类号： C12N9/16 ,  C12Q1/68

    CPC分类号： C12N9/18 ,  A01K2217/05 ,  C12Q1/6886 ,  C12Q2600/156 ,  C12Y301/01002

    摘要： This invention is directed to a DNA sequence comprising a nucleotide sequence encoding a variant paraoxonase protein and to said variant paraoxonase protein as well as to a method and a kit for detecting a risk of cancer, coronary or cerebrovascular disease, hypertension, type 2 diabetes, dementia, joint arthrosis, cataract, or sensitivity to organophosphorus compounds in a subject, the method comprising isolating genomic DNA from said subject, determining the allelic pattern for the codon 102 of the paraoxonase encoding PON1 gene in the genomic DNA, identification of Ile101Val mutation indicating said risk being increased and for targeting paraoxonase activity modulating therapies. Further this invention relates to transgenic animals comprising a human DNA molecule encoding said variant paraoxonase and to a method of phenotype-targeted gene sequencing.

    APOA-1 FUSION POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODS
    4.
    发明公开
    APOA-1 FUSION POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODS 审中-公开

    公开(公告)号：EP3328881A1

    公开(公告)日：2018-06-06

    申请号：EP16770394.1

    申请日：2016-09-06

    申请人： Theripion, Inc.

    发明人： HAYDEN-LEDBETTER, Martha S. ,  LEDBETTER, Jeffrey A. ,  MONTES, Vince

    IPC分类号： C07K14/775 ,  C12N9/18 ,  C12N9/22

    CPC分类号： C07K14/775 ,  C07K2319/30 ,  C12N9/18 ,  C12N9/22 ,  C12N15/62 ,  C12Y301/01002 ,  C12Y301/01047 ,  C12Y301/08001 ,  C12Y301/27005

    摘要： Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. The fusion polypeptides include a first polypeptide segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic, and may also include a dimerizing domain such as, e.g., an Fc region, which is typically linked carboxyl-terminal to the first polypeptide segment via a flexible linker. In some embodiments, the fusion polypeptide further includes a second polypeptide segment located carboxyl-terminal to the first polypeptide segment and which confers a second biological activity (e.g., an RNase, paraoxonase, platelet-activating factor acetylhydrolase, cholesterol ester transfer protein, lecithin-cholesterol acyltransferase, polypeptide that specifically binds to proprotein convertase subtilisin/kexin type 9, or polypeptide that specifically binds to amyloid beta). Also disclosed are dimeric proteins comprising first and second ApoA-1 fusion polypeptides as disclosed herein. The fusion polypeptides and dimeric proteins are useful in methods for therapy.

    PREVENTION AND/OR TREATMENT OF ISCHEMIA OR ISCHEMIA/REPERFUSION INJURY
    5.
    发明公开
    PREVENTION AND/OR TREATMENT OF ISCHEMIA OR ISCHEMIA/REPERFUSION INJURY 审中-公开
    预防和/或治疗缺血性或缺血/再灌注损伤

    公开(公告)号：EP3219326A1

    公开(公告)日：2017-09-20

    申请号：EP16382111.9

    申请日：2016-03-14

    申请人： Institut Catalá De Ciencies Cardiovasculars (ICCC)

    发明人： BADIMON MAESTRO, Lina ,  CUBEDO RÀFOLS, Judit ,  VILAHUR GARCÍA, Gemma ,  PADRÓ CAPMANY, Teresa

    IPC分类号： A61K38/16 ,  A61K38/47 ,  A61P9/10

    CPC分类号： C12Y301/01002 ,  A61K38/465

    摘要： The present invention relates to pharmaceutical compositions comprising a compound selected from the group consisting of: a) a polypeptide of SEQ ID NO:1, b) a functionally equivalent variant of the polypeptide according to a), c) a polynucleotide encoding a) or b), d) a vector comprising a polynucleotide according to c), e) a cell capable of secreting into the medium a polypeptide according to a) or b), and f) a nanoparticle comprising the polypeptide according to a) or b) and a pharmaceutically acceptable excipient. The invention also relates to the use of said compounds or pharmaceutical compositions for treatment and/or prevention of ischemia injury or ischemia/reperfusion injury in a subject.

    摘要翻译： 本发明涉及药物组合物，其包含选自以下的化合物：a）SEQ ID NO：1的多肽，b）a）的多肽的功能等同变体，c）编码a）或 b），d）包含根据c）的多核苷酸的载体，e）能够将根据a）或b）的多肽分泌到培养基中的细胞，以及f）包含根据a）或b）的多肽的纳米颗粒， 和药学上可接受的赋形剂。 本发明还涉及所述化合物或药物组合物用于治疗和/或预防受试者的局部缺血损伤或局部缺血/再灌注损伤的用途。